Last reviewed · How we verify

NCT05529303

Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients

Completed NA Last updated 1 February 2024
What this trial tests

NA trial testing Such as art therapy, play therapy, breathing techniques in Cervix Cancer in 80 participants. Completed in 18 September 2023.

Timeline
26 February 2023
Primary endpoint
7 May 2023
18 September 2023

Quick facts

Lead sponsorKevser Pamuk
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment80
Start date26 February 2023
Primary completion7 May 2023
Estimated completion18 September 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kevser Pamuk

Who can join

Adults 18 to 65, female only, with Cervix Cancer or Uterine Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to determine the effect of the 'Feminine Identity Improvement Program', based on cognitive behavioral and expressive techniques applied to gynecological cancer patients, on prolonged grief reactions and the perception of femininity. The study will be conducted in a randomized controlled and qualitative type with gynecological cancer patients who completed their surgical treatment at least three months ago in the last year at Afyonkarahisar Health Sciences University Hospital.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cervix Cancer

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05529303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing